List of Chapters/Sections(Table Of Content)
1 Introduction to Research & Analysis Reports
1.1 Antibody and Recombinant Protein CDMO Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Antibody and Recombinant Protein CDMO Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Antibody and Recombinant Protein CDMO Overall Market Size
2.1 Global Antibody and Recombinant Protein CDMO Market Size: 2021 VS 2028
2.2 Global Antibody and Recombinant Protein CDMO Market Size, Prospects & Forecasts: 2017-2028
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 Company Landscape
3.1 Top Antibody and Recombinant Protein CDMO Players in Global Market
3.2 Top Global Antibody and Recombinant Protein CDMO Companies Ranked by Revenue
3.3 Global Antibody and Recombinant Protein CDMO Revenue by Companies
3.4 Top 3 and Top 5 Antibody and Recombinant Protein CDMO Companies in Global Market, by Revenue in 2021
3.5 Global Companies Antibody and Recombinant Protein CDMO Product Type
3.6 Tier 1, Tier 2 and Tier 3 Antibody and Recombinant Protein CDMO Players in Global Market
3.6.1 List of Global Tier 1 Antibody and Recombinant Protein CDMO Companies
3.6.2 List of Global Tier 2 and Tier 3 Antibody and Recombinant Protein CDMO Companies
4 Market Sights by Product
4.1 Overview
4.1.1 by Type - Global Antibody and Recombinant Protein CDMO Market Size Markets, 2021 & 2028
4.1.2 Antibody CDMO
4.1.3 Recombinant Protein CDMO
4.2 By Type - Global Antibody and Recombinant Protein CDMO Revenue & Forecasts
4.2.1 By Type - Global Antibody and Recombinant Protein CDMO Revenue, 2017-2022
4.2.2 By Type - Global Antibody and Recombinant Protein CDMO Revenue, 2023-2028
4.2.3 By Type - Global Antibody and Recombinant Protein CDMO Revenue Market Share, 2017-2028
5 Sights by Application
5.1 Overview
5.1.1 By Application - Global Antibody and Recombinant Protein CDMO Market Size, 2021 & 2028
5.1.2 Pharmaceutical Company
5.1.3 Biotechnology Company
5.1.4 Generic Company
5.2 By Application - Global Antibody and Recombinant Protein CDMO Revenue & Forecasts
5.2.1 By Application - Global Antibody and Recombinant Protein CDMO Revenue, 2017-2022
5.2.2 By Application - Global Antibody and Recombinant Protein CDMO Revenue, 2023-2028
5.2.3 By Application - Global Antibody and Recombinant Protein CDMO Revenue Market Share, 2017-2028
6 Sights by Region
6.1 By Region - Global Antibody and Recombinant Protein CDMO Market Size, 2021 & 2028
6.2 By Region - Global Antibody and Recombinant Protein CDMO Revenue & Forecasts
6.2.1 By Region - Global Antibody and Recombinant Protein CDMO Revenue, 2017-2022
6.2.2 By Region - Global Antibody and Recombinant Protein CDMO Revenue, 2023-2028
6.2.3 By Region - Global Antibody and Recombinant Protein CDMO Revenue Market Share, 2017-2028
6.3 North America
6.3.1 By Country - North America Antibody and Recombinant Protein CDMO Revenue, 2017-2028
6.3.2 US Antibody and Recombinant Protein CDMO Market Size, 2017-2028
6.3.3 Canada Antibody and Recombinant Protein CDMO Market Size, 2017-2028
6.3.4 Mexico Antibody and Recombinant Protein CDMO Market Size, 2017-2028
6.4 Europe
6.4.1 By Country - Europe Antibody and Recombinant Protein CDMO Revenue, 2017-2028
6.4.2 Germany Antibody and Recombinant Protein CDMO Market Size, 2017-2028
6.4.3 France Antibody and Recombinant Protein CDMO Market Size, 2017-2028
6.4.4 U.K. Antibody and Recombinant Protein CDMO Market Size, 2017-2028
6.4.5 Italy Antibody and Recombinant Protein CDMO Market Size, 2017-2028
6.4.6 Russia Antibody and Recombinant Protein CDMO Market Size, 2017-2028
6.4.7 Nordic Countries Antibody and Recombinant Protein CDMO Market Size, 2017-2028
6.4.8 Benelux Antibody and Recombinant Protein CDMO Market Size, 2017-2028
6.5 Asia
6.5.1 By Region - Asia Antibody and Recombinant Protein CDMO Revenue, 2017-2028
6.5.2 China Antibody and Recombinant Protein CDMO Market Size, 2017-2028
6.5.3 Japan Antibody and Recombinant Protein CDMO Market Size, 2017-2028
6.5.4 South Korea Antibody and Recombinant Protein CDMO Market Size, 2017-2028
6.5.5 Southeast Asia Antibody and Recombinant Protein CDMO Market Size, 2017-2028
6.5.6 India Antibody and Recombinant Protein CDMO Market Size, 2017-2028
6.6 South America
6.6.1 By Country - South America Antibody and Recombinant Protein CDMO Revenue, 2017-2028
6.6.2 Brazil Antibody and Recombinant Protein CDMO Market Size, 2017-2028
6.6.3 Argentina Antibody and Recombinant Protein CDMO Market Size, 2017-2028
6.7 Middle East & Africa
6.7.1 By Country - Middle East & Africa Antibody and Recombinant Protein CDMO Revenue, 2017-2028
6.7.2 Turkey Antibody and Recombinant Protein CDMO Market Size, 2017-2028
6.7.3 Israel Antibody and Recombinant Protein CDMO Market Size, 2017-2028
6.7.4 Saudi Arabia Antibody and Recombinant Protein CDMO Market Size, 2017-2028
6.7.5 UAE Antibody and Recombinant Protein CDMO Market Size, 2017-2028
7 Players Profiles
7.1 Batavia Biosciences
7.1.1 Batavia Biosciences Corporate Summary
7.1.2 Batavia Biosciences Business Overview
7.1.3 Batavia Biosciences Antibody and Recombinant Protein CDMO Major Product Offerings
7.1.4 Batavia Biosciences Antibody and Recombinant Protein CDMO Revenue in Global Market (2017-2022)
7.1.5 Batavia Biosciences Key News
7.2 Grifols
7.2.1 Grifols Corporate Summary
7.2.2 Grifols Business Overview
7.2.3 Grifols Antibody and Recombinant Protein CDMO Major Product Offerings
7.2.4 Grifols Antibody and Recombinant Protein CDMO Revenue in Global Market (2017-2022)
7.2.5 Grifols Key News
7.3 Cerbios-Pharma SA
7.3.1 Cerbios-Pharma SA Corporate Summary
7.3.2 Cerbios-Pharma SA Business Overview
7.3.3 Cerbios-Pharma SA Antibody and Recombinant Protein CDMO Major Product Offerings
7.3.4 Cerbios-Pharma SA Antibody and Recombinant Protein CDMO Revenue in Global Market (2017-2022)
7.3.5 Cerbios-Pharma SA Key News
7.4 HALIX
7.4.1 HALIX Corporate Summary
7.4.2 HALIX Business Overview
7.4.3 HALIX Antibody and Recombinant Protein CDMO Major Product Offerings
7.4.4 HALIX Antibody and Recombinant Protein CDMO Revenue in Global Market (2017-2022)
7.4.5 HALIX Key News
7.5 Biovian Oy
7.5.1 Biovian Oy Corporate Summary
7.5.2 Biovian Oy Business Overview
7.5.3 Biovian Oy Antibody and Recombinant Protein CDMO Major Product Offerings
7.5.4 Biovian Oy Antibody and Recombinant Protein CDMO Revenue in Global Market (2017-2022)
7.5.5 Biovian Oy Key News
7.6 Catalent
7.6.1 Catalent Corporate Summary
7.6.2 Catalent Business Overview
7.6.3 Catalent Antibody and Recombinant Protein CDMO Major Product Offerings
7.6.4 Catalent Antibody and Recombinant Protein CDMO Revenue in Global Market (2017-2022)
7.6.5 Catalent Key News
7.7 Goodwin Biotechnology
7.7.1 Goodwin Biotechnology Corporate Summary
7.7.2 Goodwin Biotechnology Business Overview
7.7.3 Goodwin Biotechnology Antibody and Recombinant Protein CDMO Major Product Offerings
7.7.4 Goodwin Biotechnology Antibody and Recombinant Protein CDMO Revenue in Global Market (2017-2022)
7.7.5 Goodwin Biotechnology Key News
7.8 Merck
7.8.1 Merck Corporate Summary
7.8.2 Merck Business Overview
7.8.3 Merck Antibody and Recombinant Protein CDMO Major Product Offerings
7.8.4 Merck Antibody and Recombinant Protein CDMO Revenue in Global Market (2017-2022)
7.8.5 Merck Key News
7.9 Hangzhou Hs-biopharm
7.9.1 Hangzhou Hs-biopharm Corporate Summary
7.9.2 Hangzhou Hs-biopharm Business Overview
7.9.3 Hangzhou Hs-biopharm Antibody and Recombinant Protein CDMO Major Product Offerings
7.9.4 Hangzhou Hs-biopharm Antibody and Recombinant Protein CDMO Revenue in Global Market (2017-2022)
7.9.5 Hangzhou Hs-biopharm Key News
7.10 Wuxibiologics
7.10.1 Wuxibiologics Corporate Summary
7.10.2 Wuxibiologics Business Overview
7.10.3 Wuxibiologics Antibody and Recombinant Protein CDMO Major Product Offerings
7.10.4 Wuxibiologics Antibody and Recombinant Protein CDMO Revenue in Global Market (2017-2022)
7.10.5 Wuxibiologics Key News
7.11 Bioinnobio
7.11.1 Bioinnobio Corporate Summary
7.11.2 Bioinnobio Business Overview
7.11.3 Bioinnobio Antibody and Recombinant Protein CDMO Major Product Offerings
7.11.4 Bioinnobio Antibody and Recombinant Protein CDMO Revenue in Global Market (2017-2022)
7.11.5 Bioinnobio Key News
7.12 Thousand Oaks Biopharmaceuticals
7.12.1 Thousand Oaks Biopharmaceuticals Corporate Summary
7.12.2 Thousand Oaks Biopharmaceuticals Business Overview
7.12.3 Thousand Oaks Biopharmaceuticals Antibody and Recombinant Protein CDMO Major Product Offerings
7.12.4 Thousand Oaks Biopharmaceuticals Antibody and Recombinant Protein CDMO Revenue in Global Market (2017-2022)
7.12.5 Thousand Oaks Biopharmaceuticals Key News
7.13 Cerbios-Pharma SA
7.13.1 Cerbios-Pharma SA Corporate Summary
7.13.2 Cerbios-Pharma SA Business Overview
7.13.3 Cerbios-Pharma SA Antibody and Recombinant Protein CDMO Major Product Offerings
7.13.4 Cerbios-Pharma SA Antibody and Recombinant Protein CDMO Revenue in Global Market (2017-2022)
7.13.5 Cerbios-Pharma SA Key News
7.14 Eurogentec
7.14.1 Eurogentec Corporate Summary
7.14.2 Eurogentec Business Overview
7.14.3 Eurogentec Antibody and Recombinant Protein CDMO Major Product Offerings
7.14.4 Eurogentec Antibody and Recombinant Protein CDMO Revenue in Global Market (2017-2022)
7.14.5 Eurogentec Key News
7.15 HJB
7.15.1 HJB Corporate Summary
7.15.2 HJB Business Overview
7.15.3 HJB Antibody and Recombinant Protein CDMO Major Product Offerings
7.15.4 HJB Antibody and Recombinant Protein CDMO Revenue in Global Market (2017-2022)
7.15.5 HJB Key News
7.16 Bibo Pharma
7.16.1 Bibo Pharma Corporate Summary
7.16.2 Bibo Pharma Business Overview
7.16.3 Bibo Pharma Antibody and Recombinant Protein CDMO Major Product Offerings
7.16.4 Bibo Pharma Antibody and Recombinant Protein CDMO Revenue in Global Market (2017-2022)
7.16.5 Bibo Pharma Key News
7.17 MabPlex International
7.17.1 MabPlex International Corporate Summary
7.17.2 MabPlex International Business Overview
7.17.3 MabPlex International Antibody and Recombinant Protein CDMO Major Product Offerings
7.17.4 MabPlex International Antibody and Recombinant Protein CDMO Revenue in Global Market (2017-2022)
7.17.5 MabPlex International Key News
7.18 Genscriptprobio
7.18.1 Genscriptprobio Corporate Summary
7.18.2 Genscriptprobio Business Overview
7.18.3 Genscriptprobio Antibody and Recombinant Protein CDMO Major Product Offerings
7.18.4 Genscriptprobio Antibody and Recombinant Protein CDMO Revenue in Global Market (2017-2022)
7.18.5 Genscriptprobio Key News
7.19 Vetter
7.19.1 Vetter Corporate Summary
7.19.2 Vetter Business Overview
7.19.3 Vetter Antibody and Recombinant Protein CDMO Major Product Offerings
7.19.4 Vetter Antibody and Recombinant Protein CDMO Revenue in Global Market (2017-2022)
7.19.5 Vetter Key News
7.20 Etinpro (Beijing) Co
7.20.1 Etinpro (Beijing) Co Corporate Summary
7.20.2 Etinpro (Beijing) Co Business Overview
7.20.3 Etinpro (Beijing) Co Antibody and Recombinant Protein CDMO Major Product Offerings
7.20.4 Etinpro (Beijing) Co Antibody and Recombinant Protein CDMO Revenue in Global Market (2017-2022)
7.20.5 Etinpro (Beijing) Co Key News
7.21 Boehringer Ingelheim BioXcellence
7.21.1 Boehringer Ingelheim BioXcellence Corporate Summary
7.21.2 Boehringer Ingelheim BioXcellence Business Overview
7.21.3 Boehringer Ingelheim BioXcellence Antibody and Recombinant Protein CDMO Major Product Offerings
7.21.4 Boehringer Ingelheim BioXcellence Antibody and Recombinant Protein CDMO Revenue in Global Market (2017-2022)
7.21.5 Boehringer Ingelheim BioXcellence Key News
7.22 Lonza
7.22.1 Lonza Corporate Summary
7.22.2 Lonza Business Overview
7.22.3 Lonza Antibody and Recombinant Protein CDMO Major Product Offerings
7.22.4 Lonza Antibody and Recombinant Protein CDMO Revenue in Global Market (2017-2022)
7.22.5 Lonza Key News
7.23 3SBio Inc
7.23.1 3SBio Inc Corporate Summary
7.23.2 3SBio Inc Business Overview
7.23.3 3SBio Inc Antibody and Recombinant Protein CDMO Major Product Offerings
7.23.4 3SBio Inc Antibody and Recombinant Protein CDMO Revenue in Global Market (2017-2022)
7.23.5 3SBio Inc Key News
7.24 Porton
7.24.1 Porton Corporate Summary
7.24.2 Porton Business Overview
7.24.3 Porton Antibody and Recombinant Protein CDMO Major Product Offerings
7.24.4 Porton Antibody and Recombinant Protein CDMO Revenue in Global Market (2017-2022)
7.24.5 Porton Key News
8 Conclusion
9 Appendix
9.1 Note
9.2 Examples of Clients
9.3 Disclaimer
